In recent years, hybrid EMT has also been linked to acquired resistance to therapies, for example, to epithelial growth factor receptor (EGFR) and PI3K/Akt inhibitors, and the AXL tyrosine kinase receptor was found to be a common therapeutic target for several cancer types [15,16,27,29]. Here, NTRK1 is linked to cancer.